Home World News Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage... World News Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 509 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence... March 11, 2026 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Load more HOT NEWS Her Massive Weight Loss Helped Her Feel A Lump In Her... First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma Does Too Much Fructose Help Colorectal Cancers Grow? Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in...
